Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Holding TLSI?
Track your performance easily
TLSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.32 - $10.42
Previous Close$4.48
Volume67.34K
Average Volume (3M)47.03K
Market Cap
$136.60M
Enterprise Value$141.41M
Total Cash (Recent Filing)$16.48M
Total Debt (Recent Filing)$21.29M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 14, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.51
Shares Outstanding29,311,498
10 Day Avg. Volume29,468
30 Day Avg. Volume47,035
Standard Deviation0.19
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-5.44
Price to Sales (P/S)5.31
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.37
Enterprise Value/Gross Profit8.89
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$12.08Price Target Upside170.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
TriSalus Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical Expansion And Market OpportunityClinical expansion is already underway, potentially expanding the total market opportunity to over 80,000 procedures in the US annually.
Financial Performance2Q24 total revenue of $7.4M beat our estimate of ~$6.5M and consensus.
Product Innovation And Market AdoptionTriSalus's TriNav catheter significantly improves drug delivery with Pressure Enabled Drug Delivery (PEDD), which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver.
Bears Say
Revenue ForecastThe risk-adjusted revenues ascribed to nelitolimod decreased to $449M (previously $746M).
Royalty RevenueRoyalty revenue decreased to $36M (previously $56M).
Strategic PrioritizationTriSalus to deprioritize nelitolimod in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
---
Ownership Overview
19.29% Insiders
1.75% Mutual Funds
2.11% Other Institutional Investors
75.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.32 and its highest was $10.42 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
Currently, no data Available
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 14, 2024 which is 9 days ago.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 15, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.249.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -$0.35.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 30,491,072 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 0.684%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Among the largest hedge funds holding TriSalus Life Sciences’s share is Duquesne Family Office LLC. It holds TriSalus Life Sciences’s shares valued at 2M.
---
TriSalus Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.08 (170.85% Upside)
$12.08 (170.85% Upside)
Blogger Sentiment
Bearish
TLSI Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 325.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
165.01%
Trailing 12-Months
Company Description
TriSalus Life Sciences
MedTech Acquisition Corp is a blank check company.
---
TLSI Earnings Call
Q2 2024
0:00 / 0:00
---
TLSI Stock 12 Month Forecast
Average Price Target
$12.08
▲(170.85% Upside)
Technical Analysis
Best Analysts Covering TLSI
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-31.28%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -31.28% per trade.
---